The Vioxx recall is just the latest of several episodes this year that have prompted criticism of the FDA and Senate hearings. A panel talks about the drug approval process, post-marketing safety surveillance, and how the agency’s work affects Americans’ health and safety.


  • Dr. Jerry Avorn author of "Powerful Medicines," professor of medicine at Harvard Medical School, and chief of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital in Boston
  • Sen. Charles Grassley (R-Iowa), ranking member of the Senate Finance Committee
  • Marc Kaufman reporter on the national desk of "The Washington Post"
  • Alan Goldhammer, PhD associate vice president for regulatory affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA)
  • Dr. Sandra Kweder deputy director of the FDA's Office of New Drugs

Related Links

Topics + Tags


comments powered by Disqus
Most Recent Shows

Friday News Roundup – International

Friday, Oct 21 2016The Islamic State launches a counterattack in the Iraqi city of Kirkuk, as the battle to retake Mosul intensifies. Ecuador cuts off Internet access to WikiLeaks founder Julian Assange. And the president of the Philippines says his country is pivoting away from the U.S. A panel of journalists joins guest host Derek McGinty for analysis of the week's top international news stories.

Friday News Roundup – Domestic

Friday, Oct 21 2016In the final debate, Donald Trump refuses to say whether he’ll accept the election results. North Carolina officials investigate the firebombing of Republican Party headquarters. And a police chiefs’ organization apologizes for ‘historical mistreatment of minorities.’ A panel of journalists joins guest host Derek McGinty for analysis of the week's top national news stories.